Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NPB3
UPID:
CABP2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NPB3
Background:
Calcium-binding protein 2 plays a crucial role in auditory and visual systems. It is essential for sound encoding at inner hair cells synapses, primarily through the inhibition of the inactivation of voltage-gated calcium channels. Similarly, it is vital for the normal transfer of light signals in the retina.
Therapeutic significance:
The protein's link to Deafness, autosomal recessive, 93, underscores its therapeutic potential. Understanding the role of Calcium-binding protein 2 could open doors to potential therapeutic strategies for treating specific forms of deafness.